Clinical trial NCT04837131: A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Official title: A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Systemic Sclerosis
Scleroderma
Diffuse Systemic Sclerosis
Diffuse Scleroderma
Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Scleroderma
Progressive Systemic Sclerosis
Progressive Scleroderma
Scleroderma, Systemic
Scleroderma, Diffuse
Scleroderma;Progressive
Systemic Sclerosis, Diffuse
Systemic; Sclerosis, Progressive
Scleroderma of Lung
Scleroderma With Pulmonary Involvement
Systemic Sclerosis Pulmonary
Systemic Sclerosis With Lung Involvement
Interstitial Lung Disease
Pulmonary Fibrosis Interstitial
Keywords: Scleroderma
Systemic Sclerosis
Interstitial Lung Disease
Ixazomib
Mycophenolate
Treatment
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs, and its effects on overall health and quality of life.

Detailed description: The primary objective of this study is to assess the safety and tolerability of oral ixazomib taken on days 1, 8, and 15 of each 28-day treatment cycle for 6 cycles in 12 participants having diffuse systemic sclerosis/scleroderma of less than 5 years duration with non-severe interstitial lung involvement as identified from chest CT scan completed within the preceding 3 months or at study screening visit. All 12 participants will receive oral ixazomib. Reflecting the common use of mycophenolate in the management of scleroderma with complicating interstitial lung disease, 6 of 12 participants who will be enrolled will be already taking mycophenolate at a stable dose for the preceding 3 months and will be allowed to continue taking mycophenolate throughout the entire study prescribed as routine care. Ixazomib will be added to their medications. The remaining 6 of 12 participants meeting the same eligibility criteria will not be using mycophenolate or any other treatment for scleroderma interstitial lung disease at the time of enrollment and will subsequently take ixazomib study medication during participation in this study. Ixazomib dose modification or interruption is allowed for safety and tolerability reasons at any time during the study.

The secondary objective of this study is to assess the effect of ixazomib on scleroderma skin tightness/thickening and its effect on scleroderma interstitial lung disease.

The study includes approximately 13 clinic visits over up to approximately 10 months. Study procedures include medical examinations, blood tests, chest CT scans, pulmonary function tests, echocardiogram, EKG, skin biopsies, and questionnaires.

There is no cost for participation in this study.

Eligibility criteria: Inclusion Criteria:

* Male and female patients, age ≥18 years at time of signing informed written consent
* Confirmed diagnosis of diffuse cutaneous systemic sclerosis/scleroderma
* Disease duration not longer than 60 months defined as the time from the first non-Raynaud phenomenon manifestation
* Scleroderma skin thickness score (modified Rodnan skin score) between 15 and 45
* Evidence of scleroderma-related lung involvement on chest CT scan completed within the preceding 3 months or at screening study visit
* Pulmonary function testing demonstrating FVC ≥45% predicted and DLCO ≥40% predicted at screening study visit
* Resting transthoracic echocardiogram within the preceding 6 months or at screening study visit without evidence of pulmonary artery hypertension
* Stable mycophenolate dose during the preceding 3 months for those who are taking mycophenolate. Mycophenolate use is not an eligibility requirement to participate; but those participants already using mycophenolate at screening study visit will continue taking the medication throughout the entire study.
* Willingness to undergo supervised withdrawal during the first 90 days of the study of any other medication besides mycophenolate used specifically as treatment of scleroderma-related interstitial lung disease with confirmed stable pulmonary status.
* Willingness to undergo supervised withdrawal during the first 90 days of the study of any other prohibited medications with confirmed stable status.
* Able to understand and sign a written informed consent form
* Able to understand the importance of adhering to study treatment and the study protocol, and willing and able to follow all study requirements, including the concomitant medication restrictions, throughout the study
* Practice birth control requirements for sexually active female participants including option of abstinence for the entire study and for at least 90 days after the last dose of study medication
* Practice birth control requirements for sexually active male participants or partners including option of abstinence for the entire study and for at least 90 days after the last dose of study medication

Exclusion Criteria:

* Pulmonary artery hypertension under treatment
* Evidence of clinically significant pulmonary hypertension or left ventricular dysfunction with left ventricular ejection fraction \< 40% from either prior heart catheterization or resting transthoracic echocardiography within the preceding 6 months.
* Evidence of significant gastrointestinal involvement by scleroderma as assessed by the University of California, Los Angeles, Scleroderma Clinical Trial Consortium Gastrointestinal Tract multi-item questionnaire, 2.0 (\[UCLA SCTC GIT 2.0) at screening study visit.
* Known esophageal stricture sufficient to limit the ability to swallow oral medication
* Prior history of scleroderma renal crisis
* Another connective-tissue disorder (eg, rheumatoid arthritis, systemic lupus erythematosus)
* Any other significant pulmonary disorder (e.g., chronic obstructive pulmonary disease, emphysema, adult moderate to severe asthma)
* Significant environmental exposure known to cause pulmonary fibrosis including, but not limited to, drugs (e.g., amiodarone), asbestos, beryllium, radiation, or domestic birds or other exposures associated with hypersensitivity pneumonitis
* Unstable or deteriorating cardiac disease within the preceding 6 months including but not limited to unstable angina pectoris, myocardial infarction (heart attack), heart failure requiring hospitalization, poorly controlled heart arrhythmia, or significant pericardial effusion/fluid collection around the heart
* Known liver disease (e.g., chronic hepatitis or cirrhosis)
* Significant abnormality of liver function tests
* Significant kidney function impairment of any cause as evidenced by creatinine clearance \<30 mL/min
* Known active or suspected peptic (stomach) ulcer
* Known active hematologic blood-related disorder other than anemia of chronic disease or iron deficiency anemia
* Significant abnormality of blood count including hemoglobin ≤ 8.0 gm/dl, absolute neutrophil count ≤ 1000, or platelet count ≤ 75,000
* Known hematologic blood-related malignancy
* Prior stem cell or bone marrow transplant
* History of any malignancy within the last 5 years other than non-melanoma skin cell cancer cured by local resection or a carcinoma-in-situ
* Any condition likely to result in death within 12 months.
* Any condition which might be significantly worsened by the known side effects associated with ixazomib including known ≥ grade 2 peripheral neuropathy
* Tobacco smoking within 3 months of screening study visit or unwillingness to avoid smoking throughout the study (e.g., cigarette, pipe, or cigar)
* History of alcohol or substance abuse in the previous 2 years
* Any active infection including, but not limited to, bronchitis, pneumonia, sinusitis, or urinary tract infection
* Pregnancy or lactation/breast feeding
* Expectation of study participation being interrupted on account of a foreseeable medical or surgical event
* Prior use of ixazomib or other proteasome inhibitor medication
* Suspected intolerance, allergy, or hypersensitivity to ixazomib or any of its excipients
* Any prior use of rituximab
* Any prior use of cyclophosphamide
* Ongoing use within the preceding 28 days or expected use of an investigational drug (an investigational drug is defined as any drug that has not been FDA approved for marketing)
* Ongoing use or expected use of any of the following therapies: Strong inducers of a cytochrome drug metabolizing enzyme in the liver (CYP3A ). (e.g. rifampin, rifapentine, rifabutin, carbamazepine, enzalutamide, phenytoin, fosphenytoin, phenobarbital, St. John's wort)
* Ongoing use or expected use of any of the following medications: cyclophosphamide, rituximab, abatacept, nintedanib, tocilizumab, intravenous immunoglobulin (IVIG), methotrexate, leflunomide, azathioprine, sirolimus, tacrolimus, oral corticosteroids at a dose \>10 mg/d prednisone equivalent, D-penicillamine, minocycline, interferon-γ, bosentan, ambrisentan, macitentan, phosphodiesterase inhibitors (sildenafil or tadalafil for uses other than erectile dysfunction or Raynaud phenomenon), riociguat, tumor necrosis factor-α (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab, golimumab), and cyclosporine, .

Primary outcomes:
measure: Treatment-emergent Adverse Event (AE)
timeFrame: 7 months
measure: Adverse Events Leading to Ixazomib Dose Modifications
timeFrame: 7 months
measure: Adverse Events Leading to Ixazomib Early Discontinuation
timeFrame: 7 months
measure: Change in the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal 2.0 (UCLA SCTC GIT 2.0) Questionnaire Score
timeFrame: Baseline, 7 months
Secondary outcomes:
measure: Change From Baseline in Modified Rodnan Skin Score (MRSS)
timeFrame: Baseline, 24 weeks
measure: Change From Baseline in High Resolution Chest CT Scan Goh Score
timeFrame: Baseline, 24 weeks
measure: Change in Forced Vital Capacity (FVC) % Predicted.
timeFrame: Baseline, 7 months
measure: Change in Total Lung Capacity (TLC) % Predicted
timeFrame: Baseline, 24 weeks
measure: Severity of Dyspnea at Baseline (Mahler Baseline Dyspnea Index)
timeFrame: Baseline
measure: Dyspnea Status Rating (Mahler Transitional Dyspnea Index)
timeFrame: 12 weeks, 24 weeks
measure: Change in Scleroderma Health Assessment Questionnaire (SHAQ) Score
timeFrame: Baseline, 24 weeks
measure: Change in Patient Global Assessment of Disease Activity (PtGA)
timeFrame: Baseline, 24 weeks
measure: Change in Physician Global Assessment of Disease Activity (MDGA)
timeFrame: Baseline, 24 weeks
measure: Change in American College of Rheumatology Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (ACR CRISS)
timeFrame: Baseline, 24 weeks
measure: Change in Diffusion Capacity (DLCO) % Predicated
timeFrame: Baseline, 7 months
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Michael Pham, MD
role: PRINCIPAL_INVESTIGATOR
References: